The bacterial plasminogen-activator staphylokinase (Sak) is a promising thrombolytic agent for treating acute myocar- dial infarction. To effectively reduce the immunogenicity of Sak while maintaining its fibrinolyt...
To reduce the immunogenicity of recombinant staphyloki- nase, structure-based mutagenesis of Glu80 residue in wild-type staphylokinase (wt-Sak) was rationally designed and carried out by a modified QuikChange site-d...
To develop target thrombolytic agents with fibrinolytic activity, antiplatelet aggregation activity and reduced immunogenicity, two staphylokinase variants containing Arg-Gly-Asp (RGD) motif were constructed. ...